Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis

References

• Younossi ZM. Non-alcoholic fatty liver disease-a global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1002/hep.30251
   Web of Science ®Google Scholar
• Byass P. The global burden of liver disease: a challenge for methods and for public health. BMC Med. 2014;12:159. doi:10.1186/s12916-014-0141-225286285
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology. 2018. doi:10.1002/hep.30251
   Web of Science ®Google Scholar
• Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(13):3777–3785. doi:10.3748/wjg.v21.i10.293725852263
   PubMed Web of Science ®Google Scholar
• Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs. 2016;21(3):343–357. doi:10.1080/14728214.2016.122053327501374
   PubMed Web of Science ®Google Scholar
• Milic S, Mikolasevic I, Krznaric-Zrnic I, et al. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther. 2015;9:4835–4845. doi:10.2147/DDDT.S64877
   PubMed Web of Science ®Google Scholar
• Aram G, Potter JJ, Liu X, Torbenson MS, Mezey E. Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration. Hepatology (Baltimore, Md. 2008;47(6):2051–2058. doi:10.1002/hep.22149
   PubMed Web of Science ®Google Scholar
• Iwakiri Y. Nitric oxide in liver fibrosis: the role of inducible nitric oxide synthase. Clin Mol Hepatol. 2015;21(4):319–325. doi:10.3350/cmh.2015.21.4.31926770919
   PubMed Web of Science ®Google Scholar
• Anavi S, Eisenberg-Bord M, Hahn-Obercyger M, Genin O, Pines M, Tirosh O. The role of iNOS in cholesterol-induced liver fibrosis. Lab Invest. 2015;95(8):914–924. doi:10.1038/labinvest.2015.6726097999
   PubMed Web of Science ®Google Scholar
• Yasmin S, Jayaprakash V. Thiazolidinediones and PPAR orchestra as antidiabetic agents: from past to present. Eur J Med Chem. 2017;126:879–893. doi:10.1016/j.ejmech.2016.12.02027988463
   PubMed Web of Science ®Google Scholar
• Tacelli M, Celsa C, Magro B, et al. Antidiabetic drugs in NAFLD: the accomplishment of two goals at once?. Pharmaceuticals (Basel). 2018;11(4):121.
   PubMedGoogle Scholar
• Ye Y, Lin Y, Manickavasagam S, Perez-Polo JR, Tieu BC, Birnbaum Y. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2008;295(6):H2436–H2446. doi:10.1152/ajpheart.00017.200818931027
   PubMedGoogle Scholar
• Youssef J, Badr MZ. PPARs: history and advances. Methods Mol Biol. 2013;952:1–6.23100221
   PubMedGoogle Scholar
• Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177(5):633–640. doi:10.1001/jamainternmed.2016.960728241279
   PubMed Web of Science ®Google Scholar
• Ma L, Xie C, Ma Y, et al. Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases. J Med Chem. 2011;54(7):2060–2068. doi:10.1021/jm101153421381754
   PubMed Web of Science ®Google Scholar
• Xie C, Ma L, Liu J, et al. SKLB023 blocks joint inflammation and cartilage destruction in arthritis models via suppression of nuclear factor-kappa B activation in macrophage. PLoS One. 2013;8(2):e56349. doi:10.1371/journal.pone.005634923431370
   PubMedGoogle Scholar
• Feng Y, Xu J, Guo F, et al. SKLB023 hinders renal interstitial fibrosis in obstructive nephropathy by interfering TGF-β1/Smad3 signaling. RSC Adv. 2018;8(11):5891–5896. doi:10.1039/C8RA00018B
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Liu Q, et al. SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway. RSC Adv. 2018;8(54):30919–30924. doi:10.1039/C8RA04955F
   PubMed Web of Science ®Google Scholar
• Duan RL, Sun X, Liu J, Gong T, Zhang ZR. Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility. Acta Pharmacol Sin. 2011;32(1):108–115. doi:10.1038/aps.2010.20921170082
   PubMedGoogle Scholar
• Hammad MA, Muller BW. Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles. Eur J Pharm Biopharm. 1998;46(3):361–367. doi:10.1016/S0939-6411(98)00037-X9885310
   PubMed Web of Science ®Google Scholar
• Hammad MA, Muller BW. Solubility and stability of tetrazepam in mixed micelles. Eur J Pharm Sci. 1998;7(1):49–55. doi:10.1016/S0928-0987(98)00006-29845777
   PubMed Web of Science ®Google Scholar
• Teelmann K, Schlappi B, Schupbach M, Kistler A. Preclinical safety evaluation of intravenously administered mixed micelles. Arzneimittel-Forschung. 1984;34(11):1517–1523.6543126
   PubMed Web of Science ®Google Scholar
• Song X, Jiang Y, Ren C, et al. Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study. Int J Nanomedicine. 2012;7:3689–3699. doi:10.2147/IJN.S3063122888228
   PubMed Web of Science ®Google Scholar
• Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27–42. doi:10.1016/j.addr.2017.05.00728506744
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411. doi:10.1038/nrgastro.2017.3828487545
   PubMed Web of Science ®Google Scholar
• Zamin I Jr., Mattos AA, Mattos AZ, Migon E, Soares E, Perry ML. Model of experimental nonalcoholic steatohepatitis from use of methionine and choline deficient diet. Arq Gastroenterol. 2009;46(1):69–74. doi:10.1590/S0004-2803200900010001719466313
   PubMedGoogle Scholar
• He J, Hu B, Shi X, et al. Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3. Mol Cell Biol. 2013;33(10):2047–2055. doi:10.1128/MCB.00646-1223508103
   PubMed Web of Science ®Google Scholar
• Uto H, Nakanishi C, Ido A, et al. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Hepatol Res. 2005;32(4):235–242.16085455
   PubMed Web of Science ®Google Scholar
• Serfaty L. Pioglitazone: the beginning of a new era for NASH? J Hepatol. 2007;47(1):160–162. doi:10.1016/j.jhep.2007.03.00217467111
   PubMedGoogle Scholar
• Kalavalapalli S, Bril F, Koelmel JP, et al. Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. Am J Physiol Endocrinol Metab. 2018;315(2):E163–e173. doi:10.1152/ajpendo.00023.201829634314
   PubMed Web of Science ®Google Scholar
• Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72–81. doi:10.1016/j.molmed.2007.12.00318218340
   PubMed Web of Science ®Google Scholar
• Satapathy SK, Sanyal AJ. Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab. 2010;21(11):668–675. doi:10.1016/j.tem.2010.08.00320880717
   PubMedGoogle Scholar
• Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66(1):180–190. doi:10.1136/gutjnl-2016-31243127646933
   PubMed Web of Science ®Google Scholar
• Guo Q, Cai J, Li P, et al. Comparison of bile salt/phosphatidylcholine mixed micelles in solubilization to sterols and stability. Drug Des Devel Ther. 2016;10:3789–3798. doi:10.2147/DDDT.S119918
   PubMed Web of Science ®Google Scholar
• Dongowski G, Fritzsch B, Giessler J, Hartl A, Kuhlmann O, Neubert RH. The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits. Eur J Pharm Biopharm. 2005;60(1):147–151. doi:10.1016/j.ejpb.2005.01.00315848066
   PubMedGoogle Scholar
• Jiménez Calvente C, Sehgal A, Popov Y, et al. Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis. Hepatology (Baltimore, Md. 2015;62(4):1285–1297. doi:10.1002/hep.27936
   PubMed Web of Science ®Google Scholar
• Zhang S, Wu J, Wang H, et al. Liposomal oxymatrine in hepatic fibrosis treatment: formulation, in vitro and in vivo assessment. AAPS PharmSciTech. 2014;15(3):620–629. doi:10.1208/s12249-014-0086-y24515270
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760. doi:10.1038/nnano.2007.38718654426
   PubMed Web of Science ®Google Scholar